• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Vaishampayan on FGFR inhibitors and genetic testing in bladder cancer


Ulka Nitin Vaishampayan, MBBS, discusses the FGFR inhibitor erdafitinib (Balversa) and the importance of genetic/genomic testing in bladder cancer.

Erdafitinib is approved by the FDA for the treatment of adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy. Vaishampayan stresses how it is crucial that patients with bladder cancer receive genetic testing to determine their eligibility for this treatment should they progress on first-line chemotherapy.

Vaishampayan is director, Phase I Program, Rogel Cancer Center, Michigan Medicine, and professor of Internal Medicine, University of Michigan.

Related Videos
DNA strands | Image Credit: ©  Matthieu - stock.adobe.com
Keyan Salari, MD, PhD, answers a question during a Zoom video interview
Dr. Neal Shore in an interview with Urology Times
Heather L. Huelster, MD, answers a question during a Zoom video interview
DNA molecules | Image Credit: © vitstudio - stock.adobe.com
Blurred image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.